ReviewJournal of orthopaedic translation2026
Chinese expert consensus on the clinical application of stromal vascular fraction combined with bone marrow flushing for osteonecrosis of the femoral head.
Review in Journal of orthopaedic translation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteonecrosis of the femoral head (ONFH) is a common orthopedic disease that leads to severe dysfunction of the hip joint in young and middle-aged patients. Its core pathological mechanism lies in the interruption of blood supply to the femoral head and an imbalance in bone repair capacity. Traditional hip-preserving treatment methods face many limitations in promoting effective repair of the necrotic area. With the rapid development of regenerative medicine, stromal vascular fraction (SVF) therapy, due to its rich content of various repair cells and growth factors, provides a highly promising new strategy for promoting angiogenesis and bone tissue regeneration in the necrotic area. Bone marrow flushing, as a key auxiliary means to optimize the local repair microenvironment, can further enhance the therapeutic effect when combined with SVF. This expert consensus aims to systematically review the current evidence-based medical evidence and clinical practice experience of SVF combined with bone marrow flushing in the treatment of ONFH, and to clarify the core norms and operational standards for its clinical application. The article will focus on in-depth elaboration of the indications and contraindications for SVF therapy, the standardized preparation and quality control system of cell preparations, key technical points of clinical minimally invasive surgical operations (including bone marrow flushing standards), multi-dimensional efficacy evaluation methods, and prevention and management strategies for potential complications. It is intended to provide clinicians with a set of standardized and scientific practical guidelines, ultimately promoting the safe, standardized, and effective application of SVF combined with bone marrow flushing technology in the field of ONFH treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.